Device And Drug Accelerated Approval Pathways Important To Cancer Patients, US FDA Oncology Chief Pazdur Says
The Food and Drug Administration’s increased use of hastened approval pathways for innovative medical products, including new genomic device/drug combinations, has come in for criticism from some US Senators recently. But the patient group Friends of Cancer Research (FOCR) endorsed the approach at a 10 December meeting on Capitol Hill featuring FDA’s Oncology Center of Excellence director Richard Pazdur.
You may also be interested in...
US Democratic Sens. Elizabeth Warren of Massachusetts and Patty Murray of Washington State recently sent a letter to FDA officials Brett Giroir and Jeff Shuren that raises doubts about a planned bill calling for a progressive approval pathway for medical devices.
The US agency is planning to launch another accelerated device approval program along the lines of its successful Breakthrough Devices Program. But this one, the Safer Technology Program (STeP), would focus on devices with enhanced safety features.
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.